
New Agilent expansion will ‘more than double’ nucleic acid API manufacture
pharmafile | August 10, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Agilent, expansion, manufacturing, oligonucleotide
Agilent Technologies is set to expand its pharmaceutical manufacturing operations with a 20-acre facility in Weld County, Colorado.
The facility is anticipated to increase manufacturing capacity for nucleic acid active pharmaceutical ingredients by more than 100%, adding between 150 and 200 new, permanent high-salary jobs.
“The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases,” said Skip Thune, general manager of Agilent’s Nucleic Acids Solutions Division. “At Agilent, we are committed to meeting the ever-increasing needs of our customers for oligonucleotides.”
Oligonucleotides (short DNA and RNA molecules) are believed to have the potential to treat various forms of cancer, diabetes, muscular dystrophy and other disorders.
Matt Fellows
Related Content

BioDuro establishes joint manufacturing venture with Cenra
BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …

ESTEVE CDMO commences $15.5m expansion of US facility
ESTEVE CDMO, a global Contract Development and Manufacturing Organization (CDMO) specialising in small molecule active pharmaceutical …

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …





